Actor portrayal of an OPDIVO Qvantig™ patient sitting on a couch with a women as she removes his hat.

Because every second counts

Discover faster* administration with OPDIVO Qvantig® (nivolumab + hyaluronidase-nvhy), an immunotherapy treatment given by injection that is FDA approved to treat most cancer types approved for OPDIVO® (nivolumab).

Explore this injectable option

Actor portrayals.

*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary.

OPDIVO Qvantig is not indicated for co-administration with YERVOY® (ipilimumab).

Hands exploring how OPDIVO® (nivolumab) works and learning how this treatment may help fight cancer.

Explore another way you may receive treatment

You and your healthcare provider may have a choice between under-the-skin injections (subcutaneous injection) with OPDIVO Qvantig and intravenous (lV) infusions with OPDIVO

Hands perusing OPDIVO® (nivolumab) patient resources.

Helpful patient resources

Explore resources to help you along your treatment journey

Frequently asked questions about treatment with OPDIVO® (nivolumab).

Have questions about treatment?

We have answers about getting treatment, monitoring, and more

Hands exploring cost information and financial help for OPDIVO® (nivolumab).

Cost information and financial help

Find information about cost and access to OPDIVO

OPDIVO and OPDIVO Qvantig will not work for everyone. Individual results may vary.